XNYS · Diagnostics & Research
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$236.11+0.42%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
57/100
Positive
Score components
TickerWhale View
Danaher scores 57 out of 100 overall, which we rate positive. Technical is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Risk
- Sentiment Signal
What to watch
- Quality & growth
- Valuation
Quality & growth
30%45Moderate
- Revenue growth 4.6%
- EPS growth 19.8%
Valuation
25%45Moderate
- P/E 41.7
- EV/Sales 7.5
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
#73 by market cap in our coverage · ~60,000 employees · Listed 1978-12-29 · www.danaher.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#62 / 139sector rank by TickerWhale Score
TickerWhale Score 57 vs sector average 54.6 (+2.4)
Revenue growth (industry)Top 84%
Gross margin (industry)Top 35%
Return on equity (industry)Top 65%
P/E (industry)Pricier than 71%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
85/100Strong vs universe
Ranks 85th of 100 covered names on our technical composite — the composite itself scores 77/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
4 buy · 3 sell · 1 neutral of 8 votes
TickerWhale rates DHR's technical setup strong — 85th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+17.5%
- vs 50-day+6.8%
Momentum
Mixed
- RSI (14)59 · neutral
- Stochasticsell
- CCIbuy
- Williams %Rsell
Trend
Mixed
- ADX (14) trend strength29· trending
- MACD (12,26,9)sell(histogram -0.249)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 3 sell · 1 neutral.
Result — 4 buy vs 3 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)41.7
- P/S (TTM)6.7
- P/B3.2
- EV/EBITDA—
- EV/Sales7.5
- PEG2.11
Profitability & returns
- Gross margin58.5%
- Net margin16.0%
- ROE7.6%
- Debt/Equity0.51
Growth
- Revenue growth (YoY)4.6%
- EPS growth (YoY)19.8%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $167.1B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $24.6B | $23.9B | $23.9B |
| Gross profit | $14.5B | $14.2B | $14.0B |
| Operating income | $4.7B | $4.9B | $5.2B |
| Net income | $3.6B | $3.9B | $4.8B |
| EPS (diluted) | $5.05 | $5.29 | $6.38 |
| Free cash flow | $5.3B | $5.3B | $5.8B |
| Cash | $4.6B | $2.1B | $5.9B |
| Total debt | $18.4B | $16.0B | $18.4B |
| Equity | $52.5B | $49.5B | $53.5B |
| Net debt | $13.8B | $13.9B | $12.5B |
| Debt / equity | 0.35 | 0.32 | 0.34 |
| Liabilities / assets | 0.37 | 0.36 | 0.37 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DHRCurrentDanaher | 57 | 77 | 41.7 | — | 3.2 | 7.5 | $236.11 | +0.42% | +4.6% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.